These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

770 related items for PubMed ID: 23320436

  • 1. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor gemigliptin compared with sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.
    Rhee EJ, Lee WY, Min KW, Shivane VK, Sosale AR, Jang HC, Chung CH, Nam-Goong IS, Kim JA, Kim SW, Gemigliptin Study 006 Group.
    Diabetes Obes Metab; 2013 Jun; 15(6):523-30. PubMed ID: 23320436
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of initial combination therapy with gemigliptin and metformin compared with monotherapy with either drug in patients with type 2 diabetes: A double-blind randomized controlled trial (INICOM study).
    Lim S, Han KA, Yu J, Chamnan P, Kim ES, Yoon KH, Kwon S, Moon MK, Lee KW, Kim DJ, Kim M, Wongtanate M, Kim EY, Kim SH, Lee MK, INICOM Study Group.
    Diabetes Obes Metab; 2017 Jan; 19(1):87-97. PubMed ID: 27619558
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.
    Charbonnel B, Karasik A, Liu J, Wu M, Meininger G, Sitagliptin Study 020 Group.
    Diabetes Care; 2006 Dec; 29(12):2638-43. PubMed ID: 17130197
    [Abstract] [Full Text] [Related]

  • 4. A 52-week extension study of switching from gemigliptin vs sitagliptin to gemigliptin only as add-on therapy for patients with type 2 diabetes who are inadequately controlled with metformin alone.
    Jung CH, Rhee EJ, Lee WY, Min KW, Shivane VK, Sosale AR, Jang HC, Chung CH, Nam-Goong IS, Gemigliptin Study 006 Group.
    Diabetes Obes Metab; 2018 Jun; 20(6):1535-1541. PubMed ID: 29436761
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of gemigliptin, a dipeptidyl peptidase-4 inhibitor, in patients with type 2 diabetes mellitus inadequately controlled with combination treatment of metformin and sulphonylurea: a 24-week, multicentre, randomized, double-blind, placebo-controlled study (TROICA study).
    Ahn CH, Han KA, Yu JM, Nam JY, Ahn KJ, Oh TK, Lee HW, Lee DH, Kim J, Chung CH, Park TS, Kim BJ, Park SW, Park HK, Lee KJ, Kim SW, Park JH, Ko KP, Kim CH, Lee H, Jang HC, Park KS.
    Diabetes Obes Metab; 2017 May; 19(5):635-643. PubMed ID: 28026912
    [Abstract] [Full Text] [Related]

  • 6. A multicentre, multinational, randomized, placebo-controlled, double-blind, phase 3 trial to evaluate the efficacy and safety of gemigliptin (LC15-0444) in patients with type 2 diabetes.
    Yang SJ, Min KW, Gupta SK, Park JY, Shivane VK, Pitale SU, Agarwal PK, Sosale A, Gandhi P, Dharmalingam M, Mohan V, Mahesh U, Kim DM, Kim YS, Kim JA, Kim PK, Baik SH.
    Diabetes Obes Metab; 2013 May; 15(5):410-6. PubMed ID: 23170990
    [Abstract] [Full Text] [Related]

  • 7. A comparative study of the effects of a dipeptidyl peptidase-IV inhibitor and sulfonylurea on glucose variability in patients with type 2 diabetes with inadequate glycemic control on metformin.
    Kim HS, Shin JA, Lee SH, Kim ES, Cho JH, Son HY, Yoon KH.
    Diabetes Technol Ther; 2013 Oct; 15(10):810-6. PubMed ID: 24050737
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
    Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H, Stein P, Sitagliptin Study 035 Group.
    Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial.
    Nauck MA, Meininger G, Sheng D, Terranella L, Stein PP, Sitagliptin Study 024 Group.
    Diabetes Obes Metab; 2007 Mar; 9(2):194-205. PubMed ID: 17300595
    [Abstract] [Full Text] [Related]

  • 10. Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes.
    Brazg R, Xu L, Dalla Man C, Cobelli C, Thomas K, Stein PP.
    Diabetes Obes Metab; 2007 Mar; 9(2):186-93. PubMed ID: 17300594
    [Abstract] [Full Text] [Related]

  • 11. The addition of sitagliptin to ongoing metformin therapy significantly improves glycemic control in Chinese patients with type 2 diabetes.
    Yang W, Guan Y, Shentu Y, Li Z, Johnson-Levonas AO, Engel SS, Kaufman KD, Goldstein BJ, Alba M.
    J Diabetes; 2012 Sep; 4(3):227-37. PubMed ID: 22672586
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of sitagliptin added to ongoing metformin and pioglitazone combination therapy in a randomized, placebo-controlled, 26-week trial in patients with type 2 diabetes.
    Fonseca V, Staels B, Morgan JD, Shentu Y, Golm GT, Johnson-Levonas AO, Kaufman KD, Goldstein BJ, Steinberg H.
    J Diabetes Complications; 2013 Sep; 27(2):177-83. PubMed ID: 23116881
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of initial combination therapy with sitagliptin and pioglitazone in patients with type 2 diabetes: a 54-week study.
    Yoon KH, Steinberg H, Teng R, Golm GT, Lee M, O'Neill EA, Kaufman KD, Goldstein BJ.
    Diabetes Obes Metab; 2012 Aug; 14(8):745-52. PubMed ID: 22405352
    [Abstract] [Full Text] [Related]

  • 14. Randomized trial assessing the safety and efficacy of sitagliptin in Chinese patients with type 2 diabetes mellitus inadequately controlled on sulfonylurea alone or combined with metformin.
    Ba J, Han P, Yuan G, Mo Z, Pan C, Wu F, Xu L, Hanson ME, Engel SS, Shankar RR.
    J Diabetes; 2017 Jul; 9(7):667-676. PubMed ID: 27502307
    [Abstract] [Full Text] [Related]

  • 15. A treatment strategy implementing combination therapy with sitagliptin and metformin results in superior glycaemic control versus metformin monotherapy due to a low rate of addition of antihyperglycaemic agents.
    Olansky L, Reasner C, Seck TL, Williams-Herman DE, Chen M, Terranella L, Mehta A, Kaufman KD, Goldstein BJ.
    Diabetes Obes Metab; 2011 Sep; 13(9):841-9. PubMed ID: 21535346
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus.
    Scheen AJ, Charpentier G, Ostgren CJ, Hellqvist A, Gause-Nilsson I.
    Diabetes Metab Res Rev; 2010 Oct; 26(7):540-9. PubMed ID: 20824678
    [Abstract] [Full Text] [Related]

  • 17. Randomized clinical trial comparing the efficacy and safety of treatment with the once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor omarigliptin or the once-daily DPP-4 inhibitor sitagliptin in patients with type 2 diabetes inadequately controlled on metformin monotherapy.
    Goldenberg R, Gantz I, Andryuk PJ, O'Neill EA, Kaufman KD, Lai E, Wang YN, Suryawanshi S, Engel SS.
    Diabetes Obes Metab; 2017 Mar; 19(3):394-400. PubMed ID: 28093853
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of gemigliptin as add-on therapy to insulin, with or without metformin, in patients with type 2 diabetes mellitus (ZEUS II study).
    Cho YM, Deerochanawong C, Seekaew S, Suraamornkul S, Benjachareonwong S, Sattanon S, Chamnan P, Sirirak T, Kosachunhanun N, Pratipanawatr T, Suwanwalaikorn S, Lee WJ, Kim S, Choi S, Kang ES, Oh T, Kwon S, Lee MK.
    Diabetes Obes Metab; 2020 Jan; 22(1):123-127. PubMed ID: 31478335
    [Abstract] [Full Text] [Related]

  • 19. Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus.
    Aaboe K, Knop FK, Vilsbøll T, Deacon CF, Holst JJ, Madsbad S, Krarup T.
    Diabetes Obes Metab; 2010 Apr; 12(4):323-33. PubMed ID: 20380653
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 39.